drug · small molecule
azacitidine
Phase 2updated 6mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 8- drugOnureg21 co-mentions · 9 sources
- tagApproval12 co-mentions · 3 sources
- tagSmall Molecule8 co-mentions · 4 sources
- tagAML7 co-mentions · 2 sources
- tagOncology3 co-mentions · 2 sources
- tagDrug Shortage3 co-mentions · 3 sources
- tagPulmonology2 co-mentions · 1 sources
- drugivosidenib2 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 49 investigational indications.
targets
DNA (cytosine-5)-methyltransferase 1DNA (cytosine-5)-methyltransferase 3A
all catalysts(0)
nothing on the calendar yet
Trials studying azacitidine
- phase3A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
- phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- phase2Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
- phase2Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
- phase2A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
- phase2Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
- phase2A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
- phase3Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
News(2)
- BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.fiercebiotech · 2mo ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that